Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$1.9 million.

  • Eton Pharmaceuticals' Consolidated Net Income fell 40733.65% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 2191.21%. This contributed to the annual value of -$3.8 million for FY2024, which is 30844.02% down from last year.
  • Per Eton Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$1.9 million for Q3 2025, which was down 40733.65% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Consolidated Net Income ranged from a high of $5.1 million in Q1 2021 and a low of -$6.1 million during Q3 2021
  • Moreover, its 5-year median value for Consolidated Net Income was -$1.6 million (2025), whereas its average is -$1.1 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Consolidated Net Income soared by 39261.87% in 2023, and later crashed by 40733.65% in 2025.
  • Eton Pharmaceuticals' Consolidated Net Income (Quarter) stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then plummeted by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
  • Its Consolidated Net Income stands at -$1.9 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.6 million for Q1 2025.